In July 2017, the BCHC was privileged to host a visit by the Chief Executive Officer of Exosomics Siena SpA, Dr Antonio Chiesi, and its Senior Scientist, Dr Davide Zocco.
Exosomics was originally founded as a spin-out company of HansaBioMed, but has recently received significant strategic investment by Lonza, a global leader in the field of biopharmaceutical development and manufacturing. Exosomics develops new tests for cancer screening and liquid biopsy based on analysis of circulating extracellular vesicles (EVs). The company uses a patented approach for isolation of tumor-derived exosomes from blood and urine to deliver immunoassays and molecular dx assays for cancer screening, monitoring and therapy guidance.
During their visit, Dr Zocco delivered an excellent seminar outlining the interests and capabilities of Exosomics and Lonza and their visit was coupled with range of very productive discussions on exciting new areas for collaboration in exploring the methods of analysis for studying EVs in helminth research. Dr Chiesi and Dr Zocco also met with Dr Rhian Hayward, Chief Executive Officer of the Aberystwyth Innovation and Enterprise Campus (AIEC) for a conceptual tour of its upcoming world class facilities for the agri-tech industry and bio-science sector.
Our thanks to Dr Chiesi and Dr Zocco for making the long journey to Aberystwyth and we look forward to our upcoming work together!